- Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection 13 May 2024
- Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials 23 April 2024
- Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants 23 April 2024
- Mobile Applications to Support Multiple Sclerosis Communities: The Post-COVID-19 Scenario 23 April 2024
- Morphofunctional characterisation of axonal damage in different rat models of chemotherapy-induced peripheral neurotoxicity: The role of nerve excitability testing 23 April 2024
- Effect of age on metabolomic changes in a model of paclitaxel-induced peripheral neurotoxicity 23 April 2024
- Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 23 April 2024
- Vacuolar Proton-Translocating ATPase May Take Part in the Drug Resistance Phenotype of Glioma Stem Cells 13 May 2024
- Neurodegeneration: can metabolites from Eremurus persicus help? 13 May 2024
- The Role of NMNAT2/SARM1 in Neuropathy Development 13 May 2024
ENU
Experimental Neurology Unit